Close Menu

NEW YORK – Illumina and PierianDx announced Tuesday an expanded partnership for next-generation sequencing-based cancer panel reporting.

Under the terms of the agreement, PierianDx's genomic reporting products, including the Clinical Genomics Workspace and Clinical Genomics Knowledgebase, will be enabled for use with the AmpliSeq for Illumina Focus panel, AmpliSeq for Illumina Myeloid panel, and the Illumina TruSight Hereditary Cancer Panel.

Financial and other terms of the deal were not disclosed.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Moderna reports its vaccine is effective against new SARS-CoV-2 strains, though it is also developing a booster, according to the New York Times.

A new analysis suggests the B.1.1.7 strain of SARS-CoV-2 could be deadlier than previous ones, according to the Guardian.

NPR reports Merck is halting the development of its two candidate SARS-CoV-2 vaccines following disappointing Phase 1 results.

In PLOS this week: gene mutation linked to inherited venous thrombosis, lncRNA patterns in the Asian tiger mosquito, and more.